SlidesetHIVTuberculosisViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #9 LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape - Lobna GaayebView Slideset
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan GrieselView Video
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan GrieselView Slideset
VideoTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan CoxView Video
SlidesetTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan CoxView Slideset
VideoTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed MohamedView Video
SlidesetTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed MohamedView Slideset
VideoNTDTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #6 Development of Long-Acting Telacebec (Q203) for Treatment of M. tuberculosis, M. ulcerans and M. leprae - Martina KovarovaView Video
SlidesetNTDTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #6 Development of Long-Acting Telacebec (Q203) for Treatment of M. tuberculosis, M. ulcerans and M. leprae - Martina KovarovaView Slideset
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #2 Twice-Yearly Lenacapavir PrEP in Cisgender Gay Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2) - Meredith ClementView Video
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #2 Twice-Yearly Lenacapavir PrEP in Cisgender Gay Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2) - Meredith ClementView Slideset
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #5 Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV Viral Suppression, Perinatal and Neonatal Outcomes - William ShortView Video
